Condensed Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue:
License and milestone fees		$ 1,710		$ 1,710
Collaborative revenue		730		2,093
Clinical compound revenue			$ 86
Total revenue		2,440	86	3,803
Operating expenses:
Research and development	$ 9,671	5,584	28,976	13,653
General and administrative	2,102	1,865	7,195	5,609
Total operating expenses	11,773	7,449	36,171	19,262
Operating loss	(11,773)	(5,009)	(36,085)	(15,459)
Other income	176	22	498	49
Loss before benefit from income taxes	(11,597)	(4,987)	(35,587)	(15,410)
Benefit from income taxes	55	200	279	250
Net loss	$ (11,542)	$ (4,787)	$ (35,308)	$ (15,160)
Net loss per share -Basic and Diluted	$ (0.42)	$ (0.19)	$ (1.29)	$ (0.64)
Weighted average shares:
Basic and Diluted	27,282,863	25,545,164	27,275,133	23,737,443
Other comprehensive loss, net of tax of $0:
Changes in unrealized gains (losses) on available-for-sale marketable securities	$ (21)		$ 55
Total comprehensive loss	$ (11,563)	$ (4,787)	$ (35,253)	$ (15,160)